Ravi Goyal

Health Solutions

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (4)

Maria Isabel Jimenez

Health Solutions

UNITED STATES

View details

Siddharth Karanth

Health Solutions

UNITED STATES

View details

Valerie Derrien Ansquer

Health Solutions

UNITED STATES

View details

Muhammad Furqan

Associate Professor

University of Iowa Healthcare

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ravi Goyal

Research Interests

Explore related searches

Contact this professor

Articles (10)

Overall Survival With Palbociclib and Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Older Patients With HR+/HER2− Metastatic Breast Cancer

Effectiveness of standard treatments in non-small-cell lung cancer with METexon14 skipping mutation: a real-world study

Exploring the Association Between Heart Rate Control and Rehospitalization: A Real-World Analysis of Patients Hospitalized with Heart Failure with Reduced Ejection Fraction

Treatment characteristics and outcomes in lower-risk, non-del(5q) myelodysplastic syndromes: findings from a medical record review in the USA, Canada and Europe

Social Determinants of Health and Other Predictors in Initiation of Treatment with CDK4/6 Inhibitors for HR+/HER2− Metastatic Breast Cancer

Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer

Real-world outcomes in non-small-cell lung cancer patients with MET Exon 14 skipping mutation and brain metastases treated with capmatinib

Early Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Breast Cancer Treated with Eribulin After Prior Immuno-Oncology or Antibody–Drug Conjugate Therapy

Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2– metastatic breast cancer in the United States: A SEER‐Medicare population‐based study

Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2– metastatic breast cancer in the United States

Collaborators (4)

Maria Isabel Jimenez

Siddharth Karanth

Valerie Derrien Ansquer

Muhammad Furqan

Make your next move.